HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis.

Abstract
1. Opioids, though widely used as analgesics, have not been seriously considered as therapy for rheumatoid arthritis. The present study evaluated the dose-effect and time-dependence relationships of a new peripherally selective kappa agonist, asimadoline, in rats with adjuvant arthritis. 2. The arthritis was assessed by a pooled severity index combining the comprehensive criteria of oedema, radiography and histological changes, in the hind limbs. Asimadoline was extremely effective in attenuating joint damage (by up to 80%) when administered parenterally (0.5 to 10 mg kg(-1) day(-1), i.p.) throughout the disease or during its early phase; treatment was less successful if confined to the latter stages. Ten fold higher doses were effective orally. 3. Equimolar doses of a peripherally-selective antagonist, naloxone methiodide, and the kappa-selective antagonist, MR2266, fully reversed the peripheral anti-arthritic effects of asimadoline (5 mg kg(-1) day(-1)), indicating that asimadoline acts through peripheral kappa-opioid receptors. However, an equivalent dose of MR2266 did not fully reverse the anti-arthritic effects of the highest dose of asimadoline (40 mg kg(-1) day(-1)), suggesting a loss of kappa-selectivity at this dose. 4. Asimadoline also exhibited analgesic effects (mechanical nociceptive thresholds) in arthritic but not non-arthritic rats, indicating that inflammation is necessary for asimadoline-induced analgesia. 5. These data confirm our previous findings that kappa-opioids possess anti-arthritic properties and that these effects are mediated via peripheral kappa-receptors. The present results are new in showing that the peripherally acting kappa-opioid agonist, asimadoline, is a potent anti-arthritic agent. Such novel drugs, essentially lacking central side effects, herald new treatments for rheumatoid arthritis.
AuthorsW Binder, J S Walker
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 124 Issue 4 Pg. 647-54 (Jun 1998) ISSN: 0007-1188 [Print] England
PMID9690855 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Acetamides
  • Analgesics, Opioid
  • Benzomorphans
  • Narcotic Antagonists
  • Pyrrolidines
  • Quaternary Ammonium Compounds
  • Receptors, Opioid, kappa
  • Naloxone
  • MR 2266
  • N-methylnaloxone
  • asimadoline
Topics
  • Acetamides (administration & dosage, pharmacology)
  • Administration, Oral
  • Analgesics, Opioid (administration & dosage, pharmacology)
  • Animals
  • Arthritis, Experimental (physiopathology)
  • Benzomorphans (pharmacology)
  • Dose-Response Relationship, Drug
  • Male
  • Motor Activity (drug effects)
  • Naloxone (analogs & derivatives, pharmacology)
  • Narcotic Antagonists (pharmacology)
  • Pain Measurement
  • Pyrrolidines (administration & dosage, pharmacology)
  • Quaternary Ammonium Compounds
  • Rats
  • Rats, Inbred Lew
  • Receptors, Opioid, kappa (agonists, antagonists & inhibitors)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: